US FDA steps into high-price Makena preterm birth drug controversy
This article was originally published in Scrip
Executive Summary
The US FDA on 30 March threw itself into an erupting storm over the high price of KV Pharmaceuticals' drug used to prevent preterm birth, Makena (hydroxyprogesterone caproate).
You may also be interested in...
AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market
The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.